Skip to main content

Developing innovative medicines
to improve the lives of
patients and their families

At BIORCHESTRA, we develop transformational RNA medicines and delivery systems that will solve major unmet medical needs in neurodegenerative and rare diseases of the Central Nervous System.

SCIENCE

From Novel Target Discovery to First-in-Class Drug Development

Our Discovery

Our Target

Our Approach

Join our pioneering team

Join our pioneering team of world-class researchers and passionate colleagues, fighting for the health and well-being of all, including those closest to our hearts.

WHAT’S NEW

News & Press releases

Filter

Press Release

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

July 17, 2023
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary…
AD

The microRNA-485-3p concentration in salivary exosome-enriched extracellular vesicles is related to amyloid β deposition in the brain of patients with Alzheimer’s disease

July 13, 2023
Objectives Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by progressive long-term memory loss…
IR Event

[BIO2023] Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy

June 13, 2023
BIORCHESTRA is thrilled to announce that Dr. Branden RYU, our CEO, Scientific founder, and Chairman, will…

SOCIAL CHANNELS

Stay Connected